Abstract 220P
Background
Radiation oral mucositis (radiotherapy-induced oral mucositis, RIOM), as one of the common complications during radiotherapy, is difficult to avoid and predict. Severe RIOM will reduce the quality of life of patients and affect the normal progress of diagnosis and treatment. Early detection and early intervention is very important to reduce the incidence of RIOM, but at present, the sensitivity and specificity of clinical indicators for the occurrence and development of radiation stomatitis are poor, so it is necessary to study further the treatment factors and predictive indicators of radiation stomatitis. It has been found that oral flora are closely related to the progression of radiation oral mucositis.
Methods
27 postoperative patients with oral squamous cell carcinoma were enrolled in the study. The cotton swab samples of oral buccal mucosa before and after radiotherapy were collected. The diversity, species differences and marker species of the oral microbial community were determined by 16 S rRNA sequencing and metagenome sequencing.
Results
Compared with the pre-radiotherapy group, the composition of oral flora in the radiotherapy group and the post-radiotherapy group changed, and the community diversity decreased significantly. The richness of different flora was different. In terms of genera, there was a difference in the richness of Haemophilus during radiotherapy, after radiotherapy and before radiotherapy, and the number of different bacteria was positively correlated with the time of radiotherapy. At the species level, the diversity of Streptococcus pneumoniae and Haemophilus haemolyticus increased significantly after radiotherapy. In terms of functional distribution, based on KEGG and CAZymes database, there were differences in functional distribution between the two groups of oral flora.
Conclusions
Radiotherapy can change the species structure and composition of oral flora and reduce community diversity. Streptococcus pneumoniae and Haemophilus haemolyticus may be related to the occurrence and development of radiation oral mucositis.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
155P - Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1
Presenter: Anne Chiang
Session: Poster Display session
156P - Liver Metastases Correlate with Shortened Survival and Increased Dissociate Response in Patients Treated with T-Cell Engagers.
Presenter: Noé Herbel
Session: Poster Display session
157P - Preliminary results of a multicentric randomized phase I/IIa trial of an immunotherapy targeting dendritic cells (DC), CD40HVac, in patients with HPV16-positive oropharyngeal carcinoma (OPC)
Presenter: Caroline Even
Session: Poster Display session
158P - XCR1+ dendritic cell (DC) role in antitumoral response to anti PD-L1 antibody: Data from the phase Ib/II trial of DC vaccination in small cell lung cancer patients
Presenter: Maria Gonzalez Cao
Session: Poster Display session
159P - Unveiling the impact of DC vaccination on systemic immunity in advanced malignant melanoma: Preliminary results from the ABSIDE study
Presenter: Giada Sabatino
Session: Poster Display session
160P - Oral DNA vaccination targeting personalised neoantigens in immune checkpoint-inhibitor treated solid tumor patients: Interim results
Presenter: Domas Vaitiekus
Session: Poster Display session
161P - Safety of TrimelVax vaccine for patients with advanced melanoma: Clinical results
Presenter: ROBERTO ESTAY
Session: Poster Display session
162P - EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)
Presenter: Romain Cohen
Session: Poster Display session
163P - Effect of split intravenous dosing of oncolytic adenovirus TILT-123 on normal tissue versus tumor macrophages and virus bioavailability in patients with advanced solid tumors
Presenter: Elise Jirovec
Session: Poster Display session
164P - Roginolisib (IOA-244), the first highly selective oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_), has immuno-modulatory effects associated with clinical benefits in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster Display session